ProQR will host a virtual R&D event on Wednesday, March 29, 2023 from 10:00 am until 12:30 pm EDT, including an Analyst Q&A session with members of the ProQR Management Team.
During the event, the Company will showcase its proprietary Axiomer® RNA-editing technology platform, announce initial pipeline targets for internal development, and provide guidance on the advancement of programs toward the clinic. Speakers from the Company will include Daniel A. de Boer, Founder and CEO, Gerard Platenburg, Chief Scientific Officer, and René Beukema, Chief Corporate Development Officer. Peter Beal, PhD, Professor in the Department of Chemistry at the University of California at Davis and ProQR Scientific Advisory Board member will also present. In addition, the Company plans to issue its full year 2022 operating and financial results on March 29.
The presentation is available for download.
Featured Speaker Biography
Peter Beal, PhD
Dr. Beal is a Professor in the Department of Chemistry at the University of California at Davis and Director of the NIH-funded UC Davis Chemical Biology Graduate Program. For over 25 years, work in the Beal laboratory has advanced understanding of the structures and mechanism of action for the ADAR enzymes responsible for adenosine to inosine RNA editing in humans. In addition, his group has led in the development of structure-guided methods for optimizing chemically modified oligonucleotides for recruitment of RNA-binding proteins including ADARs. Beal teaches organic chemistry at the undergraduate level and several classes in nucleic acids chemistry and chemical biology at the graduate level. He has authored over 100 peer-reviewed publications in the field of RNA chemical biology and mentored over 50 Ph.D. and M.S. degree students.
ProQR is pioneering a next-generation RNA base editing technology called Axiomer®, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer® “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer® EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.